Skip to content
Screener

Myriad Genetics MYGN Q4 2025 Annual earnings

Reported February 23, 2026 · After market close

Revenue$209.8MBeat by $2.4M
EPS$0.04Beat by $0.06
Revenue estimate$207.4M
EPS estimate-$0.02

Next report

Nov 2, 2026 (in a month)
Revenue estimate$191.4M
EPS estimate-$0.16

Financials

Q4 2025

Income statement

See full
Revenue$209.8M-0.4%
Gross profit$146.8M-2.7%
Operating income-$5.7M+85.4%
Net income-$7.9M+81.4%
EPS (diluted)-$0.07+85.1%

Balance sheet

See full
Cash & equivalents$151.3M+35.2%
Total debt$209.8M+49.5%
Total equity$368.0M-47.5%
Total assets$706.6M-31.2%

Cash flow

See full
Operating cash flow$10.6M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$573.26M-54.1%
Enterprise value$631.76M-50.5%
P/S0.7×-0.8×

Profitability

See full
Gross margin69.9%0.0pp
Operating margin-47%-86.5pp
Net margin-44.4%-92.6pp

Returns & leverage

See full
Return on equity-68.5%-103pp
Debt / equity0.6×+0.4×
Current ratio2.5×+0.7×

Segments

By product

See full
Hereditary Cancer$96.8M+2.5%
Prenatal$44.9M0.0%

FAQ

When did Myriad Genetics report Q4 2025 earnings?
Myriad Genetics (MYGN) reported Q4 2025 earnings on February 23, 2026 after market close.
What were Myriad Genetics's Q4 2025 revenue and EPS?
Myriad Genetics reported revenue of $209.8M and eps of $0.04 for Q4 2025.
Did Myriad Genetics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $207.4M by $2.4M. EPS beat the consensus estimate of $-0.02 by $0.06.
How did Myriad Genetics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.4% from $210.6M a year earlier and eps grew 33.3% from $0.03.
Where can I find Myriad Genetics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000899923-26-000012) and the 10-K periodic report (0000899923-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.